1302 studies found for:    Open Studies | "Lymphatic Diseases"
Show Display Options
Rank Status Study
21 Recruiting A Study of GDC-0199 (ABT-199) in Combination With Obinutuzumab in Patients With Chronic Lymphocytic Leukemia
Condition: Lymphocytic Leukemia, Chronic
Interventions: Drug: GDC-0199 (ABT-199);   Drug: Obinutuzumab
22 Not yet recruiting Selinexor and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma
Conditions: Prolymphocytic Leukemia;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia
Interventions: Drug: Selinexor;   Drug: Ibrutinib;   Other: Pharmacological Study;   Other: Laboratory Biomarker Analysis
23 Recruiting A Study to Investigate the Safety and Efficacy of an Anti-IFNγ mAb in Children Affected by Primary Haemophagocytic Lymphohistiocytosis
Condition: Primary Hemophagocytic Lymphohistiocytosis
Intervention: Biological: NI-0501
24 Recruiting Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies
Conditions: SCID;   Omenn's Syndrome;   Reticular Dysgenesis;   Wiskott-Aldrich Syndrome;   Bare Lymphocyte Syndrome;   Common Variable Immunodeficiency;   Chronic Granulomatous Disease;   CD40 Ligand Deficiency;   Hyper IgM Syndrome;   X-linked Lymphoproliferative Disease;   Hemophagocytic Lymphohistiocytosis;   Griscelli Syndrome;   Chediak-Higashi Syndrome;   Langerhan's Cell Histiocytosis
Interventions: Drug: Alemtuzumab 0.3 mg;   Drug: Cyclophosphamide;   Drug: Busulfan;   Biological: Stem Cell Transplantation;   Drug: Fludarabine phosphate 40 mg;   Drug: Melphalan;   Drug: Alemtuzumab 0.2 mg;   Drug: Fludarabine  phosphate 30 mg;   Drug: MESNA
25 Unknown  Fludarabine and Darbepoetin Alfa in Treating Older Patients With Chronic Lymphocytic Leukemia
Conditions: Anemia;   Leukemia
Interventions: Biological: darbepoetin alfa;   Drug: fludarabine phosphate
26 Not yet recruiting GHSG-AFM13 An Open-label, Multicenter Phase II Trial With AFM13 in Patients With Relapsed or Refractory Hodgkin Lymphoma
Condition: Hodgkin Lymphoma
Intervention: Drug: AFM13
27 Recruiting Selinexor With Fludarabine and Cytarabine for Treatment of Refractory or Relapsed Leukemia or Myelodysplastic Syndrome
Conditions: Acute Myeloid Leukemia (AML);   Acute Lymphoblastic Leukemia (ALL);   Myelodysplastic Syndrome (MDS);   Mixed Phenotype Acute Leukemia (MPAL)
Interventions: Drug: Selinexor;   Drug: Fludarabine;   Drug: Cytarabine;   Drug: methotrexate/hydrocortisone/cytarabine
28 Recruiting A Phase II Prospective Study of High-dose Myeloablative Therapy, With Stem Cell Devices Support in Elderly Patients With Relapsed Aggressive Non-Hodgkin Lymphoma (NHL) or Resistant to First Line Therapy
Condition: Non Hodgkin Lymphoma
Intervention: Drug: R-DHAP/R-ICE
29 Recruiting Natural Killer (NK) Cells in Cord Blood Transplantation
Conditions: Leukemia;   Chronic Lymphocytic Leukemia
Interventions: Drug: Lenalidomide;   Drug: Fludarabine monophosphate;   Drug: Melphalan;   Procedure: NK Infusion;   Procedure: CB Infusion;   Drug: Tacrolimus;   Drug: Mycophenolate mofetil;   Drug: Rituximab
30 Unknown  Risk of Fatigue in Adolescent and Young Adult Hodgkin Lymphoma Patients
Conditions: Fatigue;   Hodgkin Lymphoma
Intervention:
31 Recruiting Ultra-Low Dose IL-2 Therapy as GVHD Prophylaxis in Haploidentical Allogeneic Stem Cell Transplantation
Conditions: Acute Lymphoblastic Leukemia (ALL);   Acute Myelogenous Leukemia (AML);   Chronic Lymphocytic Leukemia (CLL);   Chronic Myelogenous Leukemia (CML);   MDS
Intervention: Device: CliniMACS CD34 selection system
32 Recruiting Efficacy, Safety and Tolerability Study of SHAPE in IA, IB or IIA Cutaneous T-cell Lymphoma
Condition: Cutaneous T-Cell Lymphoma (CTCL)
Intervention: Drug: SHAPE
33 Recruiting A Study Evaluating the Safety and Efficacy of GDC-0199 (ABT-199) Plus Bendamustine + Rituximab (BR) in Comparison With BR or GDC-0199 Plus Rituximab in Patients With Relapsed and Refractory Follicular Non-Hodgkin's Lymphoma
Condition: Follicular Lymphoma
Interventions: Drug: Bendamustine;   Drug: GDC-0199; ABT-199; RO5537382;   Drug: Rituximab [MabThera/Rituxan]
34 Recruiting Pentostatin and Lymphocyte Infusion in Preventing Graft Rejection in Patients Who Have Undergone Donor Stem Cell Transplant
Conditions: Accelerated Phase of Disease;   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11;   Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11;   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1;   Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL;   Adult Acute Promyelocytic Leukemia With t(15;17)(q22;q12); PML-RARA;   Alkylating Agent-Related Acute Myeloid Leukemia;   Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative;   Blastic Phase;   Childhood Acute Lymphoblastic Leukemia in Remission;   Childhood Acute Myeloid Leukemia in Remission;   Childhood Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Childhood Myelodysplastic Syndrome;   Chronic Eosinophilic Leukemia, Not Otherwise Specified;   Chronic Myelomonocytic Leukemia;   Chronic Neutrophilic Leukemia;   Chronic Phase of Disease;   de Novo Myelodysplastic Syndrome;   DS Stage I Plasma Cell Myeloma;   DS Stage II Plasma Cell Myeloma;   DS Stage III Plasma Cell Myeloma;   Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue;   Juvenile Myelomonocytic Leukemia;   Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable;   Nodal Marginal Zone Lymphoma;   Previously Treated Myelodysplastic Syndrome;   Primary Myelofibrosis;   Secondary Acute Myeloid Leukemia;   Secondary Myelodysplastic Syndrome;   Splenic Marginal Zone Lymphoma;   Stage II Adult Non-Contiguous Immunoblastic Lymphoma;   Stage II Grade 1 Non-Contiguous Follicular Lymphoma;   Stage II Grade 2 Non-Contiguous Follicular Lymphoma;   Stage II Grade 3 Non-Contiguous Follicular Lymphoma;   Stage II Marginal Zone Lymphoma;   Stage II Non-Contiguous Adult Burkitt Lymphoma;   Stage II Non-Contiguous Adult Diffuse Large Cell Lymphoma;   Stage II Non-Contiguous Adult Diffuse Mixed Cell Lymphoma;   Stage II Non-Contiguous Adult Diffuse Small Cleaved Cell Lymphoma;   Stage II Non-Contiguous Adult Lymphoblastic Lymphoma;   Stage II Non-Contiguous Mantle Cell Lymphoma;   Stage II Small Lymphocytic Lymphoma;   Stage III Adult Burkitt Lymphoma;   Stage III Adult Diffuse Large Cell Lymphoma;   Stage III Adult Diffuse Mixed Cell Lymphoma;   Stage III Adult Diffuse Small Cleaved Cell Lymphoma;   Stage III Adult Hodgkin Lymphoma;   Stage III Adult Immunoblastic Lymphoma;   Stage III Adult Lymphoblastic Lymphoma;   Stage III Chronic Lymphocytic Leukemia;   Stage III Grade 1 Follicular Lymphoma;   Stage III Grade 2 Follicular Lymphoma;   Stage III Grade 3 Follicular Lymphoma;   Stage III Mantle Cell Lymphoma;   Stage III Marginal Zone Lymphoma;   Stage III Small Lymphocytic Lymphoma;   Stage IV Adult Burkitt Lymphoma;   Stage IV Adult Diffuse Large Cell Lymphoma;   Stage IV Adult Diffuse Mixed Cell Lymphoma;   Stage IV Adult Diffuse Small Cleaved Cell Lymphoma;   Stage IV Adult Hodgkin Lymphoma;   Stage IV Adult Immunoblastic Lymphoma;   Stage IV Chronic Lymphocytic Leukemia;   Stage IV Grade 1 Follicular Lymphoma;   Stage IV Grade 2 Follicular Lymphoma;   Stage IV Grade 3 Follicular Lymphoma;   Stage IV Mantle Cell Lymphoma;   Stage IV Marginal Zone Lymphoma;   Stage IV Small Lymphocytic Lymphoma
Interventions: Drug: Pentostatin;   Biological: Therapeutic Allogeneic Lymphocytes;   Drug: Mycophenolate Mofetil;   Drug: Cyclosporine
35 Recruiting Feasibility Neurocognitive Outcome After Transplant
Conditions: Stem Cell Transplantation;   Pediatric Cancer;   Acute Lymphoblastic Leukemia
Intervention: Behavioral: Cognitive rehabilitation program
36 Recruiting Efficacy of Lenalidomide in Combination With Subcutaneous Rituximab + miniCHOP in DLBCL Patients of 80 y/o or+
Condition: Diffuse Large B Cell Lymphoma
Interventions: Drug: Lenalidomide;   Drug: Rituximab
37 Recruiting Evaluation of Biochemical Markers and Clinical Investigation of Niemann-Pick Disease, Type C
Condition: Neimann-Pick Disease, Type C
Intervention:
38 Recruiting Thymus Transplantation Safety-Efficacy
Conditions: Complete DiGeorge Anomaly;   DiGeorge Syndrome;   DiGeorge Anomaly;   Complete DiGeorge Syndrome
Interventions: Biological: Thymus  Tissue for Transplantation;   Procedure: Blood Draw;   Drug: Rabbit anti-thymocyte globulin;   Drug: Cyclosporine;   Drug: Tacrolimus;   Drug: Methylprednisolone or Prednisolone;   Drug: Basiliximab;   Drug: Mycophenolate mofetil
39 Recruiting Treatment of Relapsed or Chemotherapy Refractory Chronic Lymphocytic Leukemia or Indolent B Cell Lymphoma Using Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19
Condition: Leukemia
Interventions: Biological: therapeutic autologous lymphocytes;   Drug: cyclophosphamide
40 Recruiting Dual Point PET Scan in Early Stage Hodgkin Lymphoma Patients With Bulky Lesions
Condition: Hodgkin's Lymphoma
Intervention:

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years